Interview: Lipum’s CEO about the completed phase I study with SOL-116
Umeå-based LIPUM AB has announced the successful completion of their Phase I study with SOL-116, reporting positive results.
Lipum AB
Lipum AB receives 22 MSEK for developing anti-inflammatory drug
After a thorough selection process, Lipum AB has been granted SEK 22 million from the EU’s Horizon 2020-initiative. This is a great leap forward for researchers who want to better quality of life for children and adults with chronic inflammatory diseases.